复方甲氧那明联合孟鲁司特钠治疗感染后咳嗽的临床观察 点击下载
论文标题: 复方甲氧那明联合孟鲁司特钠治疗感染后咳嗽的临床观察
英文标题:
中文摘要: 目的:观察复方甲氧那明联合孟鲁司特钠治疗感染后咳嗽的临床疗效及安全性。方法:将符合诊断标准的感染后咳嗽患者200例,按随机数字表法分为对照组和治疗组,各100例。对照组患者口服复方甲氧那明片,2粒/次,tid;治疗组患者在对照组基础上加服孟鲁司特钠片10 mg,qd。两组患者疗程均为10 d。比较两组患者治疗前后昼夜咳嗽症状评分、临床总有效率及不良反应发生情况。结果:治疗前,两组患者昼夜咳嗽评分比较,差异无统计学意义(P>0.05);治疗后,观察组患者日间咳嗽评分与夜间咳嗽评分均显著低于对照组,差异有统计学意义(P<0.05)。治疗组患者总有效率(82.00%)显著高于对照组(66.00%),差异有统计学意义(P<0.05)。两组患者均未见明显不良反应。结论:复方甲氧那明联合孟鲁司特钠治疗感染后咳嗽患者的疗效优于单用复方甲氧那明,且安全性较好。
英文摘要: OBJECTIVE: To observe the clinical efficacy and safety of Compound methoxyphenamine combined with montelukast sodium in the treatment of post-infectious cough (PIC). METHODS: 200 PIC patients meeting diagnosis criteria were randomly divided into control group and observation group, with 100 cases in each group. Control group was given Compound methoxyphenamine tablet, 2 tablets/time, tid; observation group was additionally given Montelukast sodium tablet 10 mg, qd, on the basis of control group. Treatment course lasted for 10 days. The day and night coughing score, total clinical effective rate before and after treatment and ADR in 2 groups were compared. RESULTS: Before treatment, there was no statistical significance in day and night coughing score between 2 groups (P>0.05). After treatment, the day and night coughing score of observation group were significantly lower than that of control group, with statistical significance (P<0.05). Total effective rate of observation group (82.00%) was significantly higher than that of control group (66.00%), with statistical significance (P<0.05). No sereve ADR was found in 2 groups. CONCLUSIONS: The efficacy and safety of compound methoxyphenamine combined with montelukast sodium are better than Compound methoxyphenamine alone in the treatment of PIC.
期刊: 2016年第27卷第11期
作者: 沈蔚,周文荣,张剑杰
英文作者: SHEN Wei,ZHOU Wenrong,ZHANG Jianjie
关键字: 复方甲氧那明;孟鲁司特钠;感染后咳嗽;临床疗效
KEYWORDS: Methoxyphenamine; Montelukast sodium; Post-infectious cough; Clinical efficacy
总下载数: 81次
本日下载数: 2次
本月下载数: 81次
文件大小: 619.60Kb

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!